AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9645829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4336
Study 9645829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25.0 mg/d)
Number of subjects: 4336
Study 8142860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Nifedipine
Number of subjects: 11
Study 3434628 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively ionized atmosphere
Number of subjects: 28
Study 3434628 — intervention group
Group type: COMPARATOR
Intervention: Ambient atmosphere (Control)
Number of subjects: 28
Study 29606292 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond reverse side-cut CCIs (Group A)
Number of subjects: 45
Study 29606292 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond forward side-cut CCIs (Group B)
Number of subjects: 45
Study 29606292 — intervention group
Group type: COMPARATOR
Intervention: Manual CCIs (Group C)
Number of subjects: 45
Study 27996321 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 448
Study 27996321 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (SMBG)
Number of subjects: 448
Study 24919887 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg of desogestrel/die for 5 weeks
Number of subjects: 200
Study 24919887 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of danazol/die for 5 weeks
Number of subjects: 200
Study 22929389 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1401
Study 22929389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1401
Study 15998708 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered North American ginseng (3 g)
Number of subjects: 16
Study 15998708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12023684 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 18
Study 12023684 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 18
Study 12023684 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 9895091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic-guided airway exchange of the esophageal-tracheal Combitube (ETC)
Number of subjects: 40
Study 7735418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.15 mg/kg per dose)
Number of subjects: 33
Study 7735418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline aerosol)
Number of subjects: 33
Study 1675029 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of purified gonococcal pilus vaccine given intradermally on day 1 and day 14
Number of subjects: 3123
Study 1675029 — intervention group
Group type: COMPARATOR
Intervention: Placebo given intradermally on day 1 and day 14
Number of subjects: 3123
Study 1675029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 3123
Study 6115661 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam, ketamine and nitrous oxide in oxygen
Number of subjects: 96
Study 6115661 — intervention group
Group type: COMPARATOR
Intervention: Pethidine, thiopentone, nitrous oxide in oxygen and halothane
Number of subjects: 96
Study 31240591 — intervention group
Group type: EXPERIMENTAL
Intervention: DEPART technique using indocyanine green and methylene blue for identification of arm sentinel nodes
Number of subjects: 1191
Study 31240591 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard axillary lymph node dissection without DEPART)
Number of subjects: 1191
Study 31240591 — intervention group
Group type: EXPERIMENTAL
Intervention: DEPART technique
Number of subjects: 1191
Study 31240591 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1191
Study 29258064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 169
Study 29258064 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-restorative caries treatment (NRCT)
Number of subjects: 169
Study 29258064 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorations (CR)
Number of subjects: 169
Study 25218067 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention control training
Number of subjects: 615
Study 25218067 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-bias re-training (varieties)
Number of subjects: 615
Study 25218067 — intervention group
Group type: COMPARATOR
Intervention: Sham-training control condition
Number of subjects: 615
Study 23748419 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA
Number of subjects: 97
Study 23748419 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfolds
Number of subjects: 97
Study 23748419 — intervention group
Group type: COMPARATOR
Intervention: DXA
Number of subjects: 97
Study 21457202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg subcutaneously at baseline followed by 40 mg every other week for 12 weeks
Number of subjects: 21
Study 21457202 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking injections with no active ingredient)
Number of subjects: 21
Study 18621051 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected with Plasmodium falciparum
Number of subjects: 1523
Study 18621051 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Schistosoma mansoni infection
Number of subjects: 1523
Study 18621051 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 1523
Study 18621051 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 1523
Study 18621051 — intervention group
Group type: COMPARATOR
Intervention: Uninfected children
Number of subjects: 1523
Study 16843806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable suture anchor (G II, DePuy Mitek)
Number of subjects: 124
Study 16843806 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable suture anchor (Panalok, DePuy Mitek)
Number of subjects: 124
Study 16843806 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (nonabsorbable and absorbable anchors)
Number of subjects: 124
Study 12969091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Number of subjects: 152
Study 12969091 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Number of subjects: 152
Study 11025888 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing
Number of subjects: 10
Study 11025888 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 10
Study 9131949 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumeterol
Number of subjects: 15
Study 9131949 — intervention group
Group type: EXPERIMENTAL
Intervention: GR 63411B
Number of subjects: 15
Study 9131949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8406151 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (25 micrograms subcutaneously three times daily)
Number of subjects: 8
Study 8406151 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg once a day)
Number of subjects: 8
Study 8406151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of SMS 201‐995 and omeprazole
Number of subjects: 8
Study 8406151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 20 m‐units min‐1 m‐2
Number of subjects: 5
Study 3530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 80 m‐units min‐1 m‐2
Number of subjects: 5
Study 3530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 200 m‐units min‐1 m‐2
Number of subjects: 5
Study 3530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at all three rates
Number of subjects: 5
Study 3530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at all three doses
Number of subjects: 5
Study 3530612 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 5
Study 29859968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4256
Study 29859968 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 4256
Study 27173100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin
Number of subjects: 607
Study 27173100 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 607
Study 27173100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin (CYP2C9 interacting drugs)
Number of subjects: 607
Study 27173100 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (CYP2C9 interacting drugs)
Number of subjects: 607
Study 27173100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin (mechanical heart valves)
Number of subjects: 607
Study 27173100 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (mechanical heart valves)
Number of subjects: 607
Study 27173100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin (CYP2C9 variant allele)
Number of subjects: 607
Study 27173100 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (CYP2C9 variant allele)
Number of subjects: 607
Study 24997182 — intervention group
Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg
Number of subjects: 221
Study 24997182 — intervention group
Group type: COMPARATOR
Intervention: sham injections
Number of subjects: 221
Study 22727623 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational program providing individual audit data for sensitivity, specificity, recall rate, positive predictive value, and cancer detection rate; duration not specified.
Number of subjects: 31
Study 22727623 — intervention group
Group type: COMPARATOR
Intervention: Web-based educational program (same as above)
Number of subjects: 31
Study 20042528 — intervention group
Group type: EXPERIMENTAL
Intervention: Price discounts (12.5%) on healthier foods
Number of subjects: 1104
Study 20042528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition education
Number of subjects: 1104
Study 20042528 — intervention group
Group type: EXPERIMENTAL
Intervention: Discounts plus education
Number of subjects: 1104
Study 20042528 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1104
Study 18723335 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 1776
Study 15753241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg lorazepam
Number of subjects: 15
Study 15753241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg lorazepam
Number of subjects: 15
Study 15753241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12767566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (2 mg twice daily)
Number of subjects: 251
Study 12767566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 10877197 — intervention group
Group type: EXPERIMENTAL
Intervention: STARCH
Number of subjects: 20
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of NA and 1 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of NA and 2.5 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of NA and 5 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of NA and 10 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: EXPERIMENTAL
Intervention: NA-EE2 treatments
Number of subjects: 1265
Study 8892714 — intervention group
Group type: COMPARATOR
Intervention: EE2
Number of subjects: 1265
Study 8892714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1265
Study 1676825 — intervention group
Group type: EXPERIMENTAL
Intervention: British group (unrestricted prescribing of H2-receptor antagonists)
Number of subjects: 139
Study 1676825 — intervention group
Group type: COMPARATOR
Intervention: Australian group (H2-receptor antagonists allowed only after gastroscopy or barium meal)
Number of subjects: 139
Study 6888838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 0
Study 6888838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 0
Study 6888838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 0
Study 31268641 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 115
Study 31268641 — intervention group
Group type: COMPARATOR
Intervention: Standard informing process (Control)
Number of subjects: 115
Study 28125365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 28125365 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 26094224 — intervention group
Group type: EXPERIMENTAL
Intervention: Home arm (SMS reminder + postal home collection kit)
Number of subjects: 600
Study 26094224 — intervention group
Group type: COMPARATOR
Intervention: Clinic arm (SMS alone)
Number of subjects: 600
Study 25975103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rengalin
Number of subjects: 146
Study 21636735 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Supplement (E + S) with 70 g of honey
Number of subjects: 39
Study 21636735 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E) with 70 g of artificial sweetener
Number of subjects: 39
Study 18068829 — intervention group
Group type: EXPERIMENTAL
Intervention: folkloric dance‐based exercise
Number of subjects: 40
Study 18068829 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 40
Study 17331388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol tape
Number of subjects: 233
Study 17331388 — intervention group
Group type: COMPARATOR
Intervention: Tulobuterol tablet
Number of subjects: 233
Study 15385136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sartorius transposition
Number of subjects: 61
Study 15385136 — intervention group
Group type: COMPARATOR
Intervention: No sartorius transposition (Control)
Number of subjects: 61
Study 11605106 — intervention group
Group type: EXPERIMENTAL
Intervention: Telesurgical approach
Number of subjects: 0
Study 11605106 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic approach
Number of subjects: 0
Study 10511435 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to luminance stimuli
Number of subjects: 0
Study 10511435 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to chromatic stimuli
Number of subjects: 0
Study 10511435 — intervention group
Group type: COMPARATOR
Intervention: Comparison of attended and unattended conditions
Number of subjects: 0
Study 7625475 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 9
Study 2620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg p.o. (n = 21)
Number of subjects: 36
Study 2620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg i.v. over 30 min (n = 15)
Number of subjects: 36
Study 1255322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm/kg of salt‐poor human serum albumin intravenously one hour before exchange transfusions
Number of subjects: 42
Study 1255322 — intervention group
Group type: COMPARATOR
Intervention: Simple exchanges
Number of subjects: 42
Study 29687650 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss plus whey protein supplementation (total protein: 1.2 g/kg/d)
Number of subjects: 70
Study 29687650 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and the recommended daily allowance for protein (0.8 g/kg/d)
Number of subjects: 70
Study 29687650 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (WM)
Number of subjects: 70
Study 27050056 — intervention group
Group type: EXPERIMENTAL
Intervention: LYM‐X‐SORB (LXS)
Number of subjects: 110
Study 27050056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 24941787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance equipped with ventilation
Number of subjects: 127
Study 24941787 — intervention group
Group type: COMPARATOR
Intervention: No ventilator in ambulance (comparison group)
Number of subjects: 127
Study 23095566 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 79
Study 23095566 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan haemorrhoidectomy (MMH)
Number of subjects: 79
Study 20185805 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic residents treated with at least one medication
Number of subjects: 451
Study 20185805 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic residents associated with chronic kidney disease
Number of subjects: 451
Study 20185805 — intervention group
Group type: COMPARATOR
Intervention: Residents without anemia
Number of subjects: 451
Study 18206569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercises; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15923937 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 15923937 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 0
Study 11121996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg, 50 mg, 100 mg)
Number of subjects: 315
Study 11121996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 11121996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 315
Study 9772138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy supplement (HES) 2.14 MJ/d
Number of subjects: 102
Study 9772138 — intervention group
Group type: COMPARATOR
Intervention: Low-energy supplement (LES) 0.50 MJ/d
Number of subjects: 102
Study 9772138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy supplement (HES)
Number of subjects: 102
Study 9772138 — intervention group
Group type: COMPARATOR
Intervention: Low-energy supplement (LES)
Number of subjects: 102
Study 7876659 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast echocardiography with 200 mg/ml and 400 mg/ml SHU 508A intravenously
Number of subjects: 20
Study 3207375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulsed methylprednisolone
Number of subjects: 143
Study 3207375 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study 3207375 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 143
Study 2227816 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective intestinal decontamination with norfloxacin for 7 days
Number of subjects: 14
Study 2227816 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 untreated patients)
Number of subjects: 14
Study 1105833 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-erythromycin combination (3 gm of each, day preoperatively, plus mechanical cleansing)
Number of subjects: 97
Study 1105833 — intervention group
Group type: COMPARATOR
Intervention: Other preparations
Number of subjects: 97
Study 31610826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasture only (P)
Number of subjects: 48
Study 31610826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasture plus 25% dietary DM intake as barley-based concentrate (PC25)
Number of subjects: 48
Study 31610826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasture plus 50% dietary DM intake as barley-based concentrate (PC50)
Number of subjects: 48
Study 31610826 — intervention group
Group type: COMPARATOR
Intervention: Barley-based concentrate ration (C)
Number of subjects: 48
Study 30909761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine cream
Number of subjects: 40
Study 30909761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28081990 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard volume local anesthetic administered (Group S, n=30)
Number of subjects: 60
Study 28081990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume anesthetic administered (Group L, n=30)
Number of subjects: 60
Study 28081990 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group L and Group S)
Number of subjects: 60
Study 25599541 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted transepithelial corneal collagen cross-linking (CXL)
Number of subjects: 12
Study 25599541 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted transepithelial CXL
Number of subjects: 12
Study 23649104 — intervention group
Group type: EXPERIMENTAL
Intervention: VascuLuminator
Number of subjects: 88
Study 23649104 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study 21084721 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green light delivered via cap visor in the morning
Number of subjects: 20
Study 21084721 — intervention group
Group type: COMPARATOR
Intervention: Dim red light delivered via cap visor in the morning
Number of subjects: 20
Study 19708912 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 37
Study 19708912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 37
Study 17276853 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III self-etching adhesive with Transbond XT composite resin adhesive
Number of subjects: 120
Study 17276853 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III self-etching adhesive with Fuji Ortho LC resin-modified glass ionomer cement
Number of subjects: 120
Study 17276853 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etch conditioner with Transbond XT composite resin adhesive
Number of subjects: 120